Shots:
- Biogen will utilize Envisagenics’ SpliceCore, an AI- driven RNA splicing platform to understand the regulation of different RNA isoforms in CNS cell types and will be able to access SpliceCore’s database of ~7M RNA splicing errors providing a broader perspective to evaluate splicing events
- The collaboration will identify and validate disease genetic targets to increase the success rate in the CNS drug discovery
- The addition of Envisagenics’ machine learning algorithms and high-performance computing helps to identify, test, and validate splicing errors at a large scale
Click here to read full press release/ article | Ref: GLOBE NEWSWIRE | Image: Biogen
The post Biogen and Envisagenics Enter into a Collaboration for the Advancement of RNA Splicing Research to Treat Central Nervous System Diseases first appeared on PharmaShots.